Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Oramed Pharmaceuticals, Inc.    ORMP

ORAMED PHARMACEUTICALS, INC. (ORMP)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Oramed: Fiscal 3Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/13/2018 | 12:37am CEST

JERUSALEM (AP) _ Oramed Pharmaceuticals Inc. (ORMP) on Thursday reported a loss of $4.4 million in its fiscal third quarter.

The Jerusalem-based company said it had a loss of 30 cents per share.

The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 27 cents per share.

The drug maker posted revenue of $617,000 in the period, meeting Street forecasts.

Oramed shares have declined 33 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $5.99, a fall of 28 percent in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ORMP at https://www.zacks.com/ap/ORMP

Automated Insights, source Associated Press News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ORAMED PHARMACEUTICALS, IN
09/17ORAMED PHARMACEUTICALS INC. : Other Events (form 8-K)
AQ
08/30ORAMED PHARMACEUTICALS INC. : Submission of Matters to a Vote of Security Holder..
AQ
07/13ORAMED : Fiscal 3Q Earnings Snapshot
AQ
07/12ORAMED PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..
AQ
07/11ORAMED PHARMACEUTICALS : Oral Insulin Capsule Developer Oramed Raises $18 Millio..
AQ
07/05ORAMED PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Financ..
AQ
06/26ORAMED PHARMACEUTICALS : Enrolls First Patient in Its Glucose Clamp Study for Or..
AQ
06/13ORAMED PHARMACEUTICALS : to Present at the American Diabetes Association 78th Sc..
PU
05/21ORAMED PHARMACEUTICALS : First Oral Insulin For Diabetics Takes Major Step Towar..
PU
05/10ORAMED PHARMACEUTICALS : Frost & Sullivan Publishes Quarterly Update on Oramed P..
AQ
More news
News from SeekingAlpha
09/17Oramed on go to start clinical trials on ORMD-0901 
07/03Midday Gainers / Losers (07/03/2018) 
07/03HEALTHCARE - TOP 5 GAINERS / LOSERS : 30 am (07/03/2018) 
07/03Oramed to raise $18.1M in direct equity offering 
06/18Madrigal, Galmed, And Oramed, A NASH Love Triangle 
Financials ($)
Sales 2018 2,45 M
EBIT 2018 -15,3 M
Net income 2018 -14,1 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 33,7x
Capi. / Sales 2019 12,8x
Capitalization 82,6 M
Chart ORAMED PHARMACEUTICALS, INC.
Duration : Period :
Oramed Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ORAMED PHARMACEUTICALS, IN
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 15,0 $
Spread / Average Target 215%
EPS Revisions
Managers
NameTitle
Nadav Kidron President, Chief Executive Officer & Director
Kevin L. Rakin Chairman
Joshua Hexter Chief Operating Officer & VP-Business Development
Hilla Eisenberg Chief Financial Officer, Secretary & Treasurer
Miriam Kidron Director, Chief Medical & Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ORAMED PHARMACEUTICALS, INC.-47.11%84
CELLTRION, INC.--.--%33 722
IQVIA HOLDINGS INC28.24%25 338
LONZA GROUP20.74%24 487
INCYTE CORPORATION-29.24%14 247
SEATTLE GENETICS, INC.45.25%12 094